It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
INTRODUCTION: Visfatin is a protein secreted by adipose tissue, which shows insulin mimetic properties. The role of visfatin in the development
of obesity, diabetes mellitus, and metabolic syndrome continues to raise controversy. The aim of the study was to evaluate visfatin
levels and to attempt to establish the relationship between visfatin and selected anthropometric and biochemical parameters in obese
individuals.
MATERIAL AND METHODS: The study included 68 obese subjects (15 men and 53 women) aged 37.8 ± 13.2 years with body mass index (BMI)
values of 39.4 ± 6.4 kg/m² without a previous diagnosis of abnormal glucose metabolism. The control group comprised 30 healthy nonobese
volunteers (6 men and 24 women) with normal glucose metabolism, aged 38.2 ± 14.9 years with BMI values of 22.8 ± 3.0 kg/m².
RESULTS: We found significantly higher visfatin levels in the obese subjects compared to the control group (median visfatin level of 39.6 v.
17.3 ng/ml, p = 0.0006). In the obese group there was a statistically significant negative correlation between visfatin levels and age (r = -0.26,
p = 0.034), waist-to-hip ratio (WHR) (r = -0.28, p = 0.031) and glycated haemoglobin (HbA1c) (r = -0.36, p = 0.0037). No statistically significant
correlations were found between visfatin levels and the remaining parameters under study. In the control group, visfatin levels did
not show any significant correlation with any of the parameters under study.
CONCLUSIONS: We found elevated levels of visfatin in obese subjects, which did not correlate with the majority of anthropometric parameters
with the exception of WHR (negative correlation). This correlation may suggest that elevated visfatin levels are associated with the
distribution of adipose tissue characteristic of gynoid rather than visceral obesity. In the group of obese subjects, visfatin levels decreased
with age and glycated haemoglobin levels.
(Pol J Endocrinol 2010; 61 (2): 169-173)
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Endocrinology and Diabetology with a Nuclear Medicine Laboratory, Ludwik Rydygier Medical College in Bydgoszcz, Nicolaus Copernicus University, Toruń